MX2022008286A - Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma. - Google Patents

Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma.

Info

Publication number
MX2022008286A
MX2022008286A MX2022008286A MX2022008286A MX2022008286A MX 2022008286 A MX2022008286 A MX 2022008286A MX 2022008286 A MX2022008286 A MX 2022008286A MX 2022008286 A MX2022008286 A MX 2022008286A MX 2022008286 A MX2022008286 A MX 2022008286A
Authority
MX
Mexico
Prior art keywords
crystal form
preparation
pyridopyrimidine derivative
pyridopyrimidine
derivative
Prior art date
Application number
MX2022008286A
Other languages
English (en)
Inventor
Zhenxing Du
Feng He
Qi Wu
Qiyun Shao
Lin Wang
Weidong Lu
Jun Feng
Jie Wang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2022008286A publication Critical patent/MX2022008286A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a una forma cristalina de un derivado de piridopirimidina y un método de preparación del mismo, y específicamente se refiere a la forma cristalina del compuesto de la fórmula (I) y un método de preparación del mismo; la nueva forma cristalina tiene buenas propiedades físicas y químicas, lo que facilita los tratamientos clínicos. (ver Fórmula).
MX2022008286A 2020-01-02 2020-12-31 Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma. MX2022008286A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010002822 2020-01-02
PCT/CN2020/142037 WO2021136488A1 (zh) 2020-01-02 2020-12-31 一种吡啶并嘧啶类衍生物的结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
MX2022008286A true MX2022008286A (es) 2022-08-08

Family

ID=76686512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008286A MX2022008286A (es) 2020-01-02 2020-12-31 Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma.

Country Status (10)

Country Link
US (1) US20230058425A1 (es)
EP (1) EP4085914A4 (es)
JP (1) JP2023509175A (es)
KR (1) KR20220123437A (es)
CN (1) CN114929232B (es)
AU (1) AU2020416484A1 (es)
CA (1) CA3163386A1 (es)
MX (1) MX2022008286A (es)
TW (1) TW202128692A (es)
WO (1) WO2021136488A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022184113A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 一种包含吡啶并嘧啶类衍生物的药物组合物及其制备方法
WO2024125636A1 (zh) * 2022-12-16 2024-06-20 上海拓界生物医药科技有限公司 Toll样受体调节剂与dsRNA的联合治疗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001291817A1 (en) 2000-09-26 2002-04-08 Tan, May Chuagnesanna Composition comprising a fat phase, vegetable matter and salt
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
MX2012001524A (es) 2009-08-07 2012-02-29 Glaxosmithkline Biolog Sa Derivados de oxoadenina lipidada.
EP2507237A1 (en) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011139348A2 (en) 2010-04-30 2011-11-10 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
WO2012058671A1 (en) * 2010-10-31 2012-05-03 Endo Pharmaceuticals Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
US9034336B2 (en) 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
EP3321265B1 (en) 2015-03-04 2020-05-06 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine compounds and their utilisation as modulators of toll-like receptors
EP3349757A1 (en) * 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
EP3350168B1 (en) 2015-09-17 2019-12-18 H. Hoffnabb-La Roche Ag Sulfinylphenyl or sulfonimidoylphenyl benzazepines
EP3507288B1 (en) * 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TW202415645A (zh) * 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN110526918B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法
CN115710266A (zh) * 2018-07-03 2023-02-24 江苏恒瑞医药股份有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2021136488A1 (zh) 2021-07-08
TW202128692A (zh) 2021-08-01
EP4085914A4 (en) 2023-06-21
AU2020416484A1 (en) 2022-08-25
US20230058425A1 (en) 2023-02-23
EP4085914A1 (en) 2022-11-09
CA3163386A1 (en) 2021-07-08
JP2023509175A (ja) 2023-03-07
KR20220123437A (ko) 2022-09-06
CN114929232A (zh) 2022-08-19
CN114929232B (zh) 2023-06-16

Similar Documents

Publication Publication Date Title
JOP20210065A1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
EA023631B9 (ru) Замещенные 5-фтор-1h-пиразолопиридины и их применение
MX2022008286A (es) Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma.
NO20092033L (no) Nye forbindelser
EA201890254A3 (ru) Ингибиторы глюкозилцерамидсинтазы
EP4327886A3 (en) Pyrimido- pyridazinone compounds and use thereof
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
MX2016007056A (es) Metodos para preparar compuestos de benzoquinolina.
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
AU2009306733C1 (en) Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine
MX2021012750A (es) Agonista de molécula pequeña del fxr y método de preparación para el mismo y uso del mismo.
MY149058A (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
NO20091746L (no) Nytt difenylazetidinon substituert med piperazin-1-sulfonsyre med forbedrede farmakologiske egenskaper
MX2023003264A (es) Inhibidores de cdk y su uso como productos fármaceuticos.
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
MX2023015423A (es) Ligando de acido nucleico y conjugado, metodo de preparacion y uso del mismo.
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
MX355561B (es) Proceso para hacer inhibidores de girasa y topoisomerasa iv.
EA200600878A1 (ru) Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора ( ppar )
MX2023013803A (es) Sal farmaceuticamente aceptable del derivado de pirazoloheteroarilo y forma cristalina del mismo.
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
MX2011005971A (es) Nuevas formas polimorficas de un derivado de azabiciclo-trifluorom etil benzamida.
WO2022118016A3 (en) Enzyme inhibitors
MX2024000486A (es) Tipos de sal de derivado de tetrahidroisoquinolina triciclico.